HRSA Adds Self-Collection to Screening - Scorecard - MDSpire
Advertisement
HRSA Adds Self-Collection to Screening
Updated guidelines position patient-collected testing as an option for patients aged 30 to 65 years who are at average risk of cervical cancer, with mandatory insurance coverage beginning January 2027
Clinical Scorecard: HRSA Adds Self-Collection to Screening
At a Glance
Category
Detail
Condition
Cervical Cancer Screening
Key Mechanisms
Inclusion of patient self-collection of high-risk HPV specimens as a recommended screening option.
Target Population
Average-risk patients aged 30 to 65 years.
Care Setting
Home-based or clinician's office.
Key Highlights
Self-collection of high-risk HPV specimens is now a preferred screening option.
Insurance coverage for screening services without cost-sharing begins January 1, 2027.
Primary hrHPV testing every 5 years is recommended for patients aged 30 to 65 years.
Cervical cytology every 3 years remains standard for patients aged 21 to 29 years.
Self-collection may improve access and increase screening rates, especially in underserved populations.
Guideline-Based Recommendations
Diagnosis
High-risk HPV testing is the preferred screening modality for average-risk patients aged 30 to 65 years.
Management
Additional testing (cytology, biopsy, colposcopy) is recommended if indicated.
Monitoring & Follow-up
Patients should not be screened more than once every 3 years.
Risks
Self-collection is restricted to average-risk patients; excluded populations include those with HIV, immunocompromised individuals, and those treated for cervical intraepithelial neoplasia grade 2 or higher within the past 20 years.
Patient & Prescribing Data
Average-risk patients aged 30 to 65 years.
Self-collection may occur at home or in a clinician's office, with FDA-approved tests.
Clinical Best Practices
Encourage self-collection to reduce procedural discomfort and improve access.
Utilize patient navigation services to assist with screening and follow-up.
